Observational Study on Kidney Transplant and Heart Health in CKD
This study is looking at how a kidney transplant affects the health of your heart, specifically the tiny blood vessels that supply it. People with chronic kidney disease (CKD) often have heart problems because of inflammation and changes in their blood vessels. Researchers will compare heart health in people who receive a kidney transplant to those who remain on the transplant waitlist. They will measure blood flow in your heart (using a PET scan) and your heart's pumping strength before and one year after transplant or one year after joining the study. This will help us understand if a kidney transplant can improve heart health in people with advanced CKD.
- Study design
- This is an observational study planning to enroll 80 participants. It compares two groups: those who receive a kidney transplant and those who remain on the waitlist.
- What's involved
- Participants will have heart measurements taken at the beginning of the study and again one year later.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for one year after their initial measurements.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
The Impact of Renal Transplant on Coronary Microvascular Function Among Patients With Advanced Chronic Kidney Disease
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Stress Myocardial Blood Flow (MBF)1. Transplant Arm: At baseline prior to transplant and one year after transplant 2. Waitlist Control Arm: At baseline prior to transplant and one year after baseline while remaining on the transplant waitlist
Myocardial blood flow with hyperemic stress measured on PET myocardial perfusion imaging
- Myocardial Flow Reserve (MFR)1. Transplant Arm: At baseline prior to transplant and one year after transplant 2. Waitlist Control Arm: At baseline prior to transplant and one year after baseline while remaining on the transplant waitlist
Ratio of stress and rest myocardial blood flow assessed by PET
- Left ventricular global longitudinal strain (GLS, %)1. Transplant Arm: At baseline prior to transplant and one year after transplant 2. Waitlist Control Arm: At baseline prior to transplant and one year after baseline while remaining on the transplant waitlist
Left ventricular global longitudinal strain measured on echocardiography
- Left ventricular mitral inflow velocity to mitral annular early diastolic relaxation velocity ration (E/E')1. Transplant Arm: At baseline prior to transplant and one year after transplant 2. Waitlist Control Arm: At baseline prior to transplant and one year after baseline while remaining on the transplant waitlist
E/E' measured by echocardiography
- Interleukin-6 (IL-6) levels1. Transplant Arm: At baseline prior to transplant, and 0, 2, 4, 6 and 12 months after transplant 2. Waitlist Control Arm: At baseline prior to transplant and one year after baseline while remaining on the transplant waitlist
IL-6 levels measured via proteomics assays
- Vascular Endothelial Growth Factor A (VEGF-A)1. Transplant Arm: At baseline prior to transplant, and 0, 2, 4, 6 and 12 months after transplant 2. Waitlist Control Arm: At baseline prior to transplant and one year after baseline while remaining on the transplant waitlist
VEGF-A measured by proteomic assay
- Angiopoeitin-1 (ANGPT1) Levels1. Transplant Arm: At baseline prior to transplant, and 0, 2, 4, 6 and 12 months after transplant 2. Waitlist Control Arm: At baseline prior to transplant and one year after baseline while remaining on the transplant waitlist
ANGPT1 levels measured by proteomic assay
- Angiopoeitin-2 (ANGPT2) Levels1. Transplant Arm: At baseline prior to transplant, and 0, 2, 4, 6 and 12 months after transplant 2. Waitlist Control Arm: At baseline prior to transplant and one year after baseline while remaining on the transplant waitlist
ANGPT2 levels measured by proteomics